Action 603566 PULIKE BIOLOGICAL ENGINEERING, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Pulike Biological Engineering, Inc.

Actions

603566

CNE1000025N0

Cours en clôture Shanghai S.E.
Autres places de cotation
 00:00:00 30/04/2024 		Varia. 5j. Varia. 1 janv.
17,43 CNY -.--% Graphique intraday de Pulike Biological Engineering, Inc. -3,43 % -23,05 %
25/04 Pulike Biological Engineering, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024 CI
25/04 Pulike Biological Engineering, Inc. publie ses résultats pour l'exercice clos le 31 décembre 2023 CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Pulike Biological Engineering, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Pulike Biological Engineering, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Tranche Update on Pulike Biological Engineering, Inc.'s Equity Buyback Plan announced on November 14, 2023.
Tranche Update on Pulike Biological Engineering, Inc.'s Equity Buyback Plan announced on November 14, 2023.
Pulike Biological's Vaccine for Feline Respiratory Diseases Passes Chinese Emergency Evaluation
Pulike Biological Engineering, Inc. announces an Equity Buyback for CNY 120 million worth of its shares.
Pulike Biological Engineering, Inc. authorizes a Buyback Plan.
Pulike Biological Engineering, Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023
Pulike Biological Engineering, Inc.(XSSC:603566) added to S&P Global BMI Index
Pulike Biological Engineering, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023
Pulike Biological Engineering, Inc. agreed to acquire Luoyang Lechong Health Technology Co., Ltd. from Shiji Mengbang Information Technology Co., Ltd. and Luoyang Jidi Biotechnology Center (Limited Partnership) for CNY 23.5 million.
Pulike Biological Engineering Gets Certificate for Respiratory Drug for Chickens
Pulike Biological Engineering, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Pulike Biological Engineering, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Frontier IP investee develops vaccine candidate for Streptococcus suis
Pulike Biological Engineering, Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022
Pulike Biological Engineering Unit’s New Drug Wins Registration Certificate
Pulike Biological Engineering, Inc. announced that it has received CNY 897.999976 million in funding from a group of investors
Pulike Biological Engineering, Inc. Reports Earnings Results for the Half Year Ended June 30, 2022
CAHIC ZENAQ Animal Pharmaceutical Co., Ltd announced that it expects to receive CNY 82.72 million in funding from China Animal Husbandry Industry Co., Ltd., Pulike Biological Engineering, Inc.
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action 603566
  4. Actualités Pulike Biological Engineering, Inc.
  5. Autres langues